use was measured by means of questionnaires. The uncertainty around differences in costs and cost effectiveness between the treatment groups was evaluated using bootstrapping.
Results: Seventy patients were randomised to the intervention group and 81 to the usual care group; of these, 40 in the intervention group and 48 in the control group completed all of the follow-up questionnaires.
There were no significant differences in adherence, improvements in the SCL depression mean item score and costs over 6 months between the two treatment groups. Mean total costs (2002 values) were €3275 in the intervention group and €2961 in the control group (mean difference €315; 95% CI -1922 CI - , 2416 ). The incremental cost-effectiveness ratio associated with the pharmacist intervention was €149 per 1% improvement in adherence and €2550 per point improvement in the SCL depression mean item score. Cost-effectiveness planes and acceptability curves indicated that the pharmacist intervention was not likely to be cost effective compared with usual care.
Conclusion:
In patients starting treatment with antidepressants, there were no significant differences in adherence, severity of depression, costs and cost effectiveness between patients receiving coaching by a pharmacist and patients receiving usual care after 6 months. Considering the resources needed to implement an intervention like this in clinical practice, based on these results, the continuation of usual care is recommended.
Depression is highly prevalent in the general including the pharmacological properties of the anpopulation. In a pan-European survey of depression tidepressant and patients' and providers' characterin the community, the 6-month prevalence of major istics.
[6] Multifaceted primary care interventions depression was 6.9%. [1] It is expected that depres-have been shown to improve adherence to ansion will be the second leading cause of disability (in tidepressants. [7] [8] [9] A similar effect has also been terms of disability-adjusted life-years [DALYs]) found for counselling about drug treatment.
[10] In worldwide in 2020 (11.6% of DALYs worldwide). [2] other chronic diseases, pharmacist interventions Depression is associated with increased healthcare have been shown to improve patient care and outcosts, impaired functioning and well-being, and lost comes. [11] [12] [13] [14] There is mixed evidence on the effecwork productivity.
[3] Thus, depression is associated tiveness of pharmacist interventions in the managewith substantial social and economic burdens. ment of depression. [15] [16] [17] The efficacy of antidepressants in the treatment Economic data were collected as part of a study of depression has been convincingly demonstrated to evaluate the costs and effectiveness of a pharmain randomised controlled trials. [4, 5] However, drop-cist intervention that aimed to improve adherence to out rates for antidepressant treatment are 21-33% in antidepressants and to reduce depressive symptoms. the first 4-24 weeks of antidepressant treatment. [6] This article presents the results of the economic The dropout rate is influenced by many factors, evaluation.
Methods
how to use the different study protocols for the control and intervention recipients. Patients in the control group received the standard oral and written
Setting and Participants
information that is routinely issued in The NetherForty-six pharmacists were approached to par-lands when they picked up their prescriptions at the ticipate in the study. Of these, 26 agreed to partici-pharmacy. pate in the study. Seven pharmacists stopped shortly Patients assigned to the intervention group had after the start of the study (sick leave, n = 2; time three coaching contacts during the study. The first shortage, n = 2; demotivated, n = 2; refusal by GP to contact took place at baseline and had a mean duralet patients participate in the study, n = 1), leaving tion of 20 minutes. During this contact, pharmacists 19 pharmacists. These pharmacists were located in gave the patients information about the use of anboth urban and rural areas in different parts of The tidepressants using the following list of educational Netherlands and, thus, were representative of The messages: (i) take the antidepressant daily; (ii) Netherlands. From April 2000 to April 2001, these antidepressants must be taken for 2-4 weeks for a 19 community pharmacists recruited patients. In noticeable effect; (iii) continue to take the antideThe Netherlands it is very uncommon for patients to pressant even when feeling better; (iv) do not stop visit more than one pharmacy. Inclusion criteria for taking the antidepressant without checking with a patients were (i) visiting the pharmacy with a 'new physician; and (v) do not hesitate to ask the pharmaepisode' prescription (i.e. they had not used an cist or GP if you have any questions regarding the antidepressant in the 6-month period before inclu-antidepressants. Lin et al. [21] showed that patients sion) for a non-tricyclic antidepressant from their who received these educational messages were more GP for depressive complaints; (ii) age 18 years or likely to comply during the first month of antideolder; and (iii) able to write Dutch. The protocol was pressant therapy. [21] approved by the medical ethical committee of the The patients also received a take-home video and University Medical Centre of Utrecht.
the usual written material on antidepressants. The videotape was made by the study team and reviewed
Design and Randomisation
the multifactorial origin of depression, the relation-A randomised controlled trial was performed. ship of depression to stress, physical and emotional After giving written informed consent, patients were symptoms of depression, the treatment of depresrandomly allocated to the group receiving education sion, and the importance of adherence to medication and coaching by pharmacists or to the group receiv-even if depressive symptoms improved. The study ing usual care. Dutch guidelines for the treatment of team consisted, among others, of a psychiatrist and a depression recommend continuing antidepressant pharmacist. The content of the videotape was based treatment for at least 6 months.
[18] Therefore, a fol-on expert material on depression. low-up period of 6 months was used in this study.
The second contact took place when the index The methodological details of the trial are reported prescription of antidepressants ended, and had a in more detail elsewhere. [19, 20] mean duration of 14 minutes. The number of days supply for the index prescription was 14, so the Intervention second contact took place before or at 2 weeks after All pharmacists were instructed during a plenary inclusion. The third contact took place at 3 months meeting on how to approach eligible patients and from baseline and had a mean duration of 13 min-utes. During these visits, patients were asked about consumer price index figures. [26] Discounting was adverse and/or positive effects of the antidepres-unnecessary, because neither costs nor benefits were sants. Stimulation and motivation to continue to take recorded beyond 12 months. their antidepressants was also provided.
Indirect costs caused by lost productivity were estimated using the friction cost approach. [27] The Outcome Assessments friction period was estimated to be 5 months for 2002 in The Netherlands. Calculations were based The primary outcome was adherence to the preon the mean income of the Dutch population accordscribed antidepressant therapy. Adherence was meaing to age and gender. [23] Although depression often sured by electronic pill containers (eDEMs); these causes patients to work less productively while still record the precise time of opening of the container.
being present at work (presenteeism), we did not When data from the eDEM were not available (for include this aspect in the cost-effectiveness analysis. instance, due to technical failure), data from the computerised pharmacy records were used to estiData Analysis mate adherence. At baseline and at 3 and 6 months of follow-up, depressive symptoms were measured It was calculated that 150 patients were needed using the depression 13-item subscale of the Hop-(2-sided α = 0.05, β = 0.20) to detect a difference in kins Symptom Checklist (SCL). [22] Each SCL item adherence of 13% assuming a standard deviation is scored on a 5-point scale, ranging from 1 'not at (SD) of 40%. All analyses were limited to patients all' to 5 'extremely'. A mean item score was calcu-completing all follow-up assessments (complete lated for the depression subscale.
case analysis) regardless of whether they received the assigned treatment. To maximise the contrast
Cost Measurement and Valuation
between the two treatment groups, per protocol The economic evaluation was conducted from a analyses were also performed. Patients were includsocietal perspective. Direct healthcare costs, direct ed in the per protocol analysis if the prescription for non-healthcare costs and indirect costs were esti-antidepressant medication was written out by the mated over 6 months. Information on resource use patient's GP and they completed all of the follow-up and absenteeism from paid work was obtained assessments. Patients in the intervention group were through questionnaires administered to patients at 3 excluded from the per protocol analysis if they indiand 6 months of follow-up (copies of the question-cated that they had not watched the intervention naire used are available from the author upon re-videotape or did not receive the three coaching quest). Information on medication use (including the contacts. antidepressants) during the full 6 months of the trial To compare costs between groups, confidence was obtained through the pharmacies' computerised intervals for cost differences were computed by medication records.
bias-corrected and accelerated (BCa) bootstrapping Dutch guideline prices were used to value re-with 2000 replications. [28] A cost-effectiveness analsource use. [23, 24] If these were not available, tariffs ysis was performed in which the primary clinical were used. Table I lists the cost categories and prices outcome of the trial was expressed as mean adherused in the economic evaluation. The costs of medi-ence within each group over 6 months of follow-up. cation were estimated on the basis of the prices The SCL depression score was expressed as the established by the Royal Dutch Society for Pharma-mean improvement within each group between cy. [25] All costs were adjusted to 2002 values using baseline and 6 months of follow-up. Incremental Company doctor (visit of ≤20 minutes) 20.80
Indirect costs
Absenteeism from paid labour (per day) g Depending on age and gender
Intervention costs
25-Minute take-home video h 3.78
Drug coaching contacts at the pharmacy (per hour) 52.94 a €1 = $US1.27.
b Price according to recently published Dutch guidelines. [23] c d Physiotherapy within the Mensendieck tradition may be described as active exercise treatment and functional training, in which the patient through action, experience and recognition gains insight into his/her own situation, potential and limitations. As well as instructing, the physiotherapist acts as a counsellor.
e Haptonomy is the science of affectivity and is based on relating through psychotactile contact.
f Mean of the price according to two or more therapists (magnetic therapist: four therapists; spiritualist: three therapists; reflexologist: two therapists).
g Indirect costs for paid labour were calculated according to the friction cost approach on the basis of the mean income of the Dutch population stratified for age and gender. [23] h Cost of duplication only; the costs of production were not included in the base-case analysis.
cost-effectiveness ratios were calculated in which rected percentile method with 5000 replications. [29] the difference in costs between intervention subjects The bootstrapped incremental cost/effect pairs were and control subjects was divided by the difference in plotted on a cost-effectiveness plane [30] and were effects between both groups. The uncertainty associused to calculate a cost-effectiveness acceptability ated with the incremental cost-effectiveness ratios was calculated by bootstrapping using the bias-cor-curve. 
Sensitivity Analysis

Results
In three sensitivity analyses, uncertainties in the A total of 151 patients were included in the trial; variables and assumptions employed in the main 70 patients were randomised to the intervention analysis were varied in order to evaluate their influ-group and 81 to the usual care group. This difference ence on the estimated results. [32] In the first sensitivi-in the number of patients per treatment group is ty analysis the costs of producing the videotape were caused by the fact that block randomisation was included in the price of the videotape, while in the used to ensure equal numbers of intervention and base-case analysis only the costs of duplicating the control patients per pharmacy. The baseline quesvideotape were included. In the second sensitivity tionnaire was returned by 135 patients (64 from the analysis, the indirect costs for lost productivity asso-intervention group and 71 from the control group). ciated with paid labour were calculated according to At the 3-and 6-month follow-up visits, 106 and 98 the human capital approach to enable comparisons patients, respectively, returned their follow-up queswith other studies. Complete follow-up on SCL tionnaires. Complete follow-up through questiondepression scores, healthcare utilisation and work naires was available for 89 patients (41 from the days lost was available for only 89 patients (61%). intervention group and 48 from the control group). Therefore, in the third sensitivity analysis the influ-Of these, one patient from the intervention group ence of imputing the mean value per treatment was excluded because medication data were missing group for missing values in patients who did not (see figure 1) . Patients with higher levels of educacomplete all follow-up assessments was evaluated. tion were more likely to complete all of the followImputation was limited to patients who had complet-up assessments. Thirty-eight of the 70 patients ed the baseline assessment.
(54%) included in the intervention group, and 34 of the 40 (85%) in this group who completed all of the of follow-up. As can be seen, there were no signififollow-up questionnaires, indicated that they had cant differences in resource use between the interwatched the educational video at least once. The vention and control group. Visits to healthcare provintervention and control groups did not differ in the iders were mainly restricted to GPs and psycholodemographic and prognostic characteristics mea-gists. Twelve (30%) patients in the intervention sured at baseline (table II) . Although the difference group and ten (21%) patients in the control group in the percentage of married patients and the mean each received >15 prescriptions of medication over duration of depressive complaints was rather large 6 months (including prescriptions for antidepresbetween the intervention and control groups, this sants). was not statistically significant. At baseline, 26 patients (65%) in the intervention group had a paid job compared with 34 patients Clinical Effects (71%) in the control group. During the trial, 10 (25%) patients in the intervention group and 18 A full evaluation of the effects of coaching and (38%) in the control group had been absent from education by pharmacists on adherence and deprespaid labour, of which 5 (13%) and 8 (17%) patients, sive symptoms has been reported elsewhere. [19, 20] In respectively, were absent for 1-5 months, and 2 summary, mean adherence did not differ significant-(5%) and 2 (4%) patients were absent for the full 6 ly between the intervention group (88%) and the months, respectively. control group (86%) at 6 months (mean difference 2.1%; 95% CI -5.6, 9.8). At 6 months there were Costs also no statistically significant differences between the two groups with regards to the improvements on Table IV lists the mean costs per treatment group the SCL depression scale, with a slight benefit being and the differences in mean costs between the shown with the pharmacist intervention (mean difgroups over 6 months. In both groups, the main ference -0.15; 95% CI -0.54, 0.23).
contributor to total costs was indirect costs. There were no statistically significant differences in direct,
Utilisation of Healthcare Resources
indirect or total costs. Direct non-healthcare costs Table III presents the resource use and work were higher in the control group because of more absenteeism that was reported during the 6 months visits to alternative therapists. 
Cost-Effectiveness Analyses
two percent of the incremental cost/effect pairs were located in the northeast quadrant, 30% in the southeast quadrant, 11% in the southwest quadrant and The incremental cost-effectiveness ratio for 17% in the northwest quadrant, confirming the findcoaching and education by pharmacists compared ings of no statistically significant differences in with usual care was €149 per 1% improvement in costs and effects. The incremental cost-effectiveness adherence and €2550 per point improvement in the plane for improvement in the SCL depression score SCL depression mean item score. The incremental showed similar results (data not shown). Figure 3 cost-effectiveness plane for adherence shows that presents the cost-effectiveness acceptability curve there is a great deal of uncertainty around the costeffectiveness ratio for adherence (figure 2). Forty-for adherence. This curve shows that decision mak- c Primary care is defined as care that is directly accessible by patients.
d Secondary care is defined as care for which patients need a referral.
e Patient costs consist of costs of alternative therapists, which are generally paid by the patients themselves.
f Since there is no variation in intervention costs within the groups, SDs and 95% confidence intervals can not be calculated.
Sensitivity Analysis
In the first sensitivity analysis, the costs of producing the video were included in the intervention costs, resulting in a cost of €95.52 for the videotape. Direct healthcare costs in the intervention group increased to a mean of €818 (SD 482). This did not materially influence the results.
In the next sensitivity analysis, the indirect costs for paid labour were calculated using the human capital approach. This resulted in higher indirect and total costs in both groups. Mean indirect and total costs were €2733 (SD 5353) and €3458 (SD 5510), respectively, in the intervention group and €2402 (SD 5424) and €3112 (SD 5631), respectively, in ers should have little belief that coaching and educathe control group. These changes had little impact tion by pharmacists is cost effective as a means of on the results. increasing adherence to antidepressants compared Table V shows the direct, indirect and total costs with usual care.
after imputation of the mean value per treatment group in cases of missing values, resulting in some-
Per Protocol Analysis
what lower direct, indirect and total costs in both groups. The difference in direct costs between the The per protocol analysis was restricted to pa-treatment groups increased, while the differences in tients who had completed all follow-up assessments indirect and total costs decreased slightly. The difand fulfilled the criteria for per protocol analysis (26 ferences in direct, indirect and total costs between intervention and 45 control group patients). In this the two groups were not statistically significant. The analysis there were no significant differences in differences in clinical outcomes and the cost-effecadherence (mean difference 4.2; 95% CI -4.7, 13.1) and improvements in the mean SCL depression item score (mean difference -0.27; 95% CI -0.69, 0.16) between the treatment groups. Total costs in both groups were higher than in the previous analysis. The difference in total costs between the two treatment groups was also somewhat larger, but was still not statistically significant (mean difference €507; 95% CI -1667, 3132). The incremental cost per 1% improvement in adherence was €120 and the incremental cost per point improvement in SCL depression mean item score was €2375. This analysis also did not show the intervention to be more costeffective than usual care. tiveness ratios did not change substantially between
Of three studies evaluating the effectiveness of the sensitivity analysis and the base-case analysis.
more intensive pharmacist interventions to improve adherence to antidepressants, [15] [16] [17] two found signifDiscussion icant effects on adherence rates. [16, 17] Thus, a possible explanation for the non-significant difference in This study evaluated the cost effectiveness of a adherence between the two treatment groups in our pharmacy-based intervention to improve adherence study is that the intervention tested was not intensive to antidepressants in primary care. After 6 months of enough. We deliberately chose a minimal intervenfollow-up there were no significant differences in tion that was easy to implement without disrupting adherence or in improvements in the mean SCL the pharmacist's daily practice too much. Neverthedepression item score between the two treatment less, many patients did not complete all follow-up groups. Indirect costs were the main determinants of visits, or the visits were timed too late -as reflected total costs: almost 80% of total costs in both groups in the small number of patients included in the per consisted of indirect costs. Total costs were slightly protocol analysis. The per protocol analysis that was higher, but not by a statistically significant amount, not limited to patients completing all follow-up asin the intervention group. The cost-effectiveness sessments and that was reported in the accompanyplanes showed that there was substantial uncertainty ing clinical paper, [20] showed that adherence was around the cost-effectiveness ratios. The per protosignificantly higher in the intervention group than in col analysis also showed no significant differences the control group. Thus, better implementation of a in clinical outcomes or costs between the two groups minimal intervention like the one tested in this study after 6 months. may prove beneficial. However, we could not repliSeveral studies by Katon and colleagues [7] [8] [9] 33, 34] cate these results because of missing cost data. have shown that multifaceted primary care interven-
The present study has several strengths. First, tions, directed at both the patient and their physiadherence was measured by eDEMs, which record cian, can lead to significant improvements in adherthe precise times at which the container is opened. ence to adequate dosages of antidepressant medicaThis method approaches a gold standard for measurtion accompanied by moderate increases in costs.
ing adherence.
[35] Secondly, complete medication Peveler et al. [10] demonstrated that counselling by data were available for all patients except one who nurses had an effect on the duration of treatment, completed the baseline questionnaire. Thirdly, comwhile information leaflets had no effect. In their plete data on adherence were available either study, there were no significant differences in the through the eDEM or, in the case of technical number of GP visits, hospital admissions, or work problems with the eDEM, through data on antidedays lost, but the costs and cost effectiveness were pressant refills. Finally, the new setting of this study not compared.
-the community pharmacy -should be mentioned. tion costs had been included, this would not have As GPs may not have time to provide drug coaching, influenced the results of this study. community pharmacists could take over this task. [19] Fifth, sample size calculations showed that 150 There are also some limitations to our study. patients would be needed to show a relevant 13% First, patients knew from the start that adherence difference in adherence. Although 151 patients were was the primary outcome of the study and that it was included, baseline data were available for only 135 measured by the eDEM. This may explain why patients and complete follow-up was available for adherence was higher than in other studies using only 88 patients. Therefore, the study was unelectronic pill containers in which patients were not derpowered to detect significant differences in adinformed about the use of the device or the primary herence. However, even when all patients for whom objective of the study. [36, 37] It is also possible that the a baseline measurement was available were includuse of the eDEM in itself positively influenced ed in the study, the difference in adherence between adherence. In either case, mean adherence rates the two treatment groups was small (3%) and nonwere rather high, leaving little room for further significant (95% CI -7.3, 13.3). [20] We expect that improvement.
this difference in adherence would not have been larger if more patients were included in the study, Second, block randomisation was used in this because withdrawal rates were equal in the two study. It is possible that, despite instructions to groups. As cost data are highly variable, studies pharmacists on how to use different protocols for the comparing costs require greater sample sizes than patients in the control and intervention groups, [20] there was contamination of usual care with elements studies comparing clinical effects. Thus, the study of the intervention. This may also partly explain the was also underpowered to detect significant differremarkably high adherence rates in the control ences in costs. However, it is considered unfeasible group. However, this seems unlikely, since patients and unethical to continue a trial beyond the point at in the intervention group were much more satisfied which the clinical efficacy of the intervention has about their pharmacist's care than usual care pa-been shown. [40] Therefore, most trials have sample tients.
sizes based on the expected clinical outcomes, which was also the case here. Third, the withdrawal rate was quite high, and adherence was significantly higher in patients with Finally, in this study, the main analyses were complete follow-up. Therefore, in the sensitivity limited to patients who completed all follow-up analysis the mean per treatment group was imputed questionnaires and for whom complete medication for missing values in order to increase the statistical data from the pharmacies' computerised medication power of the study. In this analysis there were no records were available. In general, complete case significant differences in clinical outcomes, costs or analyses are considered inefficient. However, since cost effectiveness between both groups. cost data are in general heavily skewed, imputation may bias the results. [41] Nevertheless, we performed A fourth limitation is that costs of hospitalisaa sensitivity analysis in which we imputed the mean tions were not explicitly asked for. However, several per treatment group for missing data. This may also other cost-effectiveness studies of interventions in lead to biased estimates, but the amount of bias depressed primary care patients demonstrated no seems to be acceptable when the dropout is comsignificant differences in hospitalisation costs. [38, 39] pletely at random. [42] Hence, it is reasonable to assume that if hospitalisa- mended.
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